Chronic lymphocytic leukemia cells acquire regulatory B-cell properties in response to TLR9 and CD40 activation

Area of Science:

• Immunology
• Hematology
• Cell Biology

Background:

• Circulating chronic lymphocytic leukemia (CLL) cells share phenotypic similarities with regulatory B-cells (Bregs).
• Bregs are known to suppress immune responses, primarily through Interleukin-10 (IL-10) production.
• Understanding Breg properties in CLL is crucial for deciphering immune dysregulation in the disease.

Purpose of the Study:

• To identify and characterize the regulatory B-cell (Breg) properties of chronic lymphocytic leukemia (CLL) cells.
• To investigate the role of Interleukin-10 (IL-10) in mediating the suppressive functions of CLL cells.
• To explore the impact of Toll-like receptor 9 (TLR9) and CD40 activation on CLL cell regulatory functions.

Main Methods:

• Peripheral blood B-cells and T-cells were isolated from untreated CLL patients.
• Co-culture assays were performed to assess the ability of CLL cells to suppress autologous T-cell immune responses.
• IL-10 production and T-cell proliferation were measured following stimulation with TLR9 or CD40 agonists.

Main Results:

• TLR9 activation of CLL cells increased regulatory T-cell (Treg) frequency and suppressed autologous T-cell proliferation.
• This TLR9-mediated suppression was dependent on IL-10 generation by CLL cells.
• CD40 activation increased Treg frequency but did not affect IL-10 production or T-cell proliferation.

Conclusions:

• CLL cells possess unique clonal regulatory B-cell (Breg) properties that modulate T-cell responses.
• TLR9 activation is a potent stimulus for inducing Breg-like functions in CLL cells, potentially contributing to immune evasion.
• These findings highlight a novel mechanism of immune modulation in CLL, driven by TLR9-responsive CLL cells.